Clinical Trials List
2024-10-15 - 2025-10-31
Phase II
Recruiting5
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 黃柏翔 Division of General Surgery
- 李宜軒 Division of General Surgery
- 林季宏 Division of General Surgery
- 張端瑩 Division of General Surgery
- 羅喬 Division of General Surgery
- 林柏翰 Division of General Surgery
- 陳怡君 Division of General Surgery
- YEN-SHEN LU Division of General Surgery
- 蔡立威 Division of General Surgery
- 郭文宏 Division of General Surgery
- Wei-Wu Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jui-Hung Tsai Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
- Zhu-Jun Loh Division of General Surgery
- 楊舜如 Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 蕭聖諺 Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Ling Kuo 無
- Mengting Peng 無
- Chi-Chang Yu 無
- Wen-Chi Shen 無
- 周旭桓 無
- Chan-Keng Yang 無
- 沈士哲 無
- Yung-Chang Lin 無
- 阮昱翔 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
118 participants